Skip to content

Caring and soothing properties of a topical Waid Cream in dry and itchy skin

Caring and soothing properties of a topical Waid Cream in dry and itchy skin - Waid Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011125
Enrollment
50
Registered
2016-09-28
Start date
2016-12-06
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry, irritated, itchy skin L85.3

Interventions

Group 1: Topical body lotion (Waid Cream) made of lipids, moisturisers and containing extract from Woad (Isatis Tinctoria). Twice daily application for two weeks on dry body-skin areas. Amount applie

Sponsors

Medicos Service GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Dry, itchy, irritated skin (Body and extremities) Male and female subjects Pruritus intensity minim. NRS 3 No systemic therapy in the last 2 weeks or no systemic antihistamine medication and no topical therapy for the past week Informed consent Agreement to stop using the currently applying body-care products and to replace them by the study product Agreement to follow carefully the to the study related obligations and the advices of the investigators .

Exclusion criteria

Exclusion criteria: Dry, itchy, irritated skin only in the face For female subjects: Pregnancy or lactation Active psychosomatic or psychiatric diseases Clear unstable or uncontrolled medical condition, diagnosed by the Investigator (e.g. cardiovascular, immunologic, haematological, hepatic, neurological, endocrine, gastrointestinal, urogenital, soft tissue concerning incidents or diseasesI Existence of an active systemic or dermatologic infection Known active malign basic disease Drug- or alcohol abuse, medicines abuse identified by the investigator Topical use of Tacrolimus, Pimecrolimus, Polidocanol, Menthol, Cannabinoidagonists or Capsaicin in the last week preceding the study Oral intake of Steroids, Cyclosporin A, or other immunsupressiva, Naltrexone, UV-therapy, in the two last weeks preceding the start of the study Oral intake of antihistaminic drugs in the last week preceding the onset of the study Acute exacerbation of a dermatosis or of cutaneous infections Known allergy or sensitivity to one or more of the components of the study preparation Participation to an other clinical study in the month preceding the inclusion to this study Employee of the CRO or of the Sponsor or near relatives (partner, kids, parents, sisters and brothers, or kids of them) of an employee

Design outcomes

Primary

MeasureTime frame
Cosmetic caring properties of Waid Cream. Assessment via questionnaire and by measurement of skin hydration (corneometry) and of transepidermal water loss before starting and after two weeks of twice daily application.

Secondary

MeasureTime frame
Soothing potential (Itch, burning, stinging), and application of the new validated 5PLQ questionnaire in dry skin. Assessments before and after two weeks of twice daily application.

Countries

Germany

Contacts

Public ContactPhilipp Stein

Medicos Service GmbH

philipp.stein@dermasence.de+49 251 91599 303

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026